Christopher V Plowe

List of Publications by Year
in descending order

181 papers	16,959 citations	20759 60 h-index	16127 124 g-index
186 all docs	186 docs citations	186 times ranked	10280 citing authors

#	Article	IF	Citations
1	Malaria chemoprevention and drug resistance: a review of the literature and policy implications. Malaria Journal, 2022, 21, 104.	0.8	46
2	An In Silico Analysis of Malaria Pre-Erythrocytic-Stage Antigens Interpreting Worldwide Genetic Data to Suggest Vaccine Candidate Variants and Epitopes. Microorganisms, 2022, 10, 1090.	1.6	2
3	Serologic and Cytokine Profiles of Children with Concurrent Cerebral Malaria and Severe Malarial Anemia Are Distinct from Other Subtypes of Severe Malaria. American Journal of Tropical Medicine and Hygiene, 2022, 107, 315-319.	0.6	3
4	Revisiting Co-trimoxazole Prophylaxis for African Adults in the Era of Antiretroviral Therapy: A Randomized Controlled Clinical Trial. Clinical Infectious Diseases, 2021, 73, 1058-1065.	2.9	8
5	Selection of pfcrt K76 and pfmdr1 N86 Coding Alleles after Uncomplicated Malaria Treatment by Artemether-Lumefantrine in Mali. International Journal of Molecular Sciences, 2021, 22, 6057.	1.8	7
6	High-throughput detection of eukaryotic parasites and arboviruses in mosquitoes. Biology Open, 2021, 10, .	0.6	2
7	Malian adults maintain serologic responses to virulent PfEMP1s amid seasonal patterns of fluctuation. Scientific Reports, 2021, 11, 14401.	1.6	2
8	Immunoprofiles associated with controlled human malaria infection and naturally acquired immunity identify a shared IgA pre-erythrocytic immunoproteome. Npj Vaccines, 2021, 6, 115.	2.9	2
9	Antibody signatures of asymptomatic Plasmodium falciparum malaria infections measured from dried blood spots. Malaria Journal, 2021, 20, 378.	0.8	6
10	Epitope-Specific Antibody Responses to a Plasmodium falciparum Subunit Vaccine Target in a Malaria-Endemic Population. Journal of Infectious Diseases, 2021, 223, 1943-1947.	1.9	3
11	Successful Profiling of Plasmodium falciparum var Gene Expression in Clinical Samples via a Custom Capture Array. MSystems, 2021, 6, e0022621.	1.7	4
12	Strains used in whole organism Plasmodium falciparum vaccine trials differ in genome structure, sequence, and immunogenic potential. Genome Medicine, 2020, 12, 6.	3.6	61
13	Epitope-based sieve analysis of Plasmodium falciparum sequences from a FMP2.1/AS02A vaccine trial is consistent with differential vaccine efficacy against immunologically relevant AMA1 variants. Vaccine, 2020, 38, 5700-5706.	1.7	5
14	No evidence of amplified Plasmodium falciparum plasmepsin II gene copy number in an area with artemisinin-resistant malaria along the Chinaâ€“Myanmar border. Malaria Journal, 2020, 19, 334.	0.8	5
15	Microarray analyses reveal strain-specific antibody responses to Plasmodium falciparum apical membrane antigen 1 variants following natural infection and vaccination. Scientific Reports, 2020, 10, 3952.	1.6	24
16	Detecting geospatial patterns of Plasmodium falciparum parasite migration in Cambodia using optimized estimated effective migration surfaces. International Journal of Health Geographics, 2020, 19, 13.	1.2	2
17	Genomic Epidemiology of Antimalarial Drug Resistance in Plasmodium falciparum in Southern China. Frontiers in Cellular and Infection Microbiology, 2020, 10, 610985.	1.8	0
18	Malaria Exposure in Ann Township, Myanmar, as a Function of Land Cover and Land Use: Combining Satellite Earth Observations and Field Surveys. GeoHealth, 2020, 4, e2020GH000299.	1.9	5

#	Article	IF	Citations
19	Host and Parasite Transcriptomic Changes upon Successive Plasmodium falciparum Infections in Early Childhood. MSystems, 2020, 5, .	1.7	7
20	Artemetherâ€“Lumefantrine and Dihydroartemisininâ€“Piperaquine Retain High Efficacy for Treatment of Uncomplicated Plasmodium falciparum Malaria in Myanmar. American Journal of Tropical Medicine and Hygiene, 2020, 102, 598-604.	0.6	6
21	Dose-Dependent Infectivity of Aseptic, Purified, Cryopreserved Plasmodium falciparum 7G8 Sporozoites in Malaria-Naive Adults. Journal of Infectious Diseases, 2019, 220, 1962-1966.	1.9	17
22	Serologic responses to the PfEMP1 DBL-CIDR head structure may be a better indicator of malaria exposure than those to the DBL-Î± tag. Malaria Journal, 2019, 18, 273.	0.8	6
23	Immunoglobulin G subclass and antibody avidity responses in Malian children immunized with Plasmodium falciparum apical membrane antigen 1 vaccine candidate FMP2.1/AS02A. Malaria Journal, 2019, 18, 13.	0.8	8
24	Genomic structure and diversity of Plasmodium falciparum in Southeast Asia reveal recent parasite migration patterns. Nature Communications, 2019, 10, 2665.	5.8	46
25	Antibodies to Peptides in Semiconserved Domains of RIFINs and STEVORs Correlate with Malaria Exposure. MSphere, 2019, 4, .	1.3	23
26	Beyond Blood Smears: Qualification of Plasmodium 18S rRNA as a Biomarker for Controlled Human Malaria Infections. American Journal of Tropical Medicine and Hygiene, 2019, 100, 1466-1476.	0.6	41
27	Children with cerebral malaria or severe malarial anaemia lack immunity to distinct variant surface antigen subsets. Scientific Reports, 2018, 8, 6281.	1.6	31
28	Antibody Profiling by Proteome Microarray with Multiplex Isotype Detection Reveals Overlap between Human and Aotus nancymaae Controlled Malaria Infections. Proteomics, 2018, 18, 1700277.	1.3	14
29	Two complement receptor one alleles have opposing associations with cerebral malaria and interact with Î±+thalassaemia. ELife, 2018, 7, .	2.8	25
30	Malaria severity: Possible influence of the E670G PCSK9 polymorphism: A preliminary case-control study in Malian children. PLoS ONE, 2018, 13, e0192850.	1.1	12
31	Extent and Dynamics of Polymorphism in the Malaria Vaccine Candidate Plasmodium falciparum Reticulocyteâ€“Binding Protein Homologue-5 in Kalifabougou, Mali. American Journal of Tropical Medicine and Hygiene, 2018, 99, 43-50.	0.6	10
32	Professor Ogobara K. Doumbo (1956â€“June 9, 2018). American Journal of Tropical Medicine and Hygiene, 2018, 99, 1118-1119.	0.6	0
33	Attenuated PfSPZ Vaccine induces strain-transcending T cells and durable protection against heterologous controlled human malaria infection. Proceedings of the National Academy of Sciences of the United States of America, 2017, 114, 2711-2716.	3.3	201
34	Mother-Newborn Pairs in Malawi Have Similar Antibody Repertoires to Diverse Malaria Antigens. Vaccine Journal, 2017, 24, .	3.2	3
35	Association of a Novel Mutation in the Plasmodium falciparum Chloroquine Resistance Transporter With Decreased Piperaquine Sensitivity. Journal of Infectious Diseases, 2017, 216, 468-476.	1.9	102
36	New var reconstruction algorithm exposes high var sequence diversity in a single geographic location in Mali. Genome Medicine, 2017, 9, 30.	3.6	13

#	Article	IF	Citations
37	A novel method for extracting nucleic acids from dried blood spots for ultrasensitive detection of low-densityÂPlasmodium falciparum and Plasmodium vivaxÂinfections. Malaria Journal, 2017, 16, 377.	0.8	56
38	Strain-specific Plasmodium falciparum growth inhibition among Malian children immunized with a blood-stage malaria vaccine. PLoS ONE, 2017, 12, e0173294.	1.1	14
39	A new method for sequencing the hypervariable Plasmodium falciparum gene var2csa from clinical samples. Malaria Journal, 2017, 16, 343.	0.8	12
40	Long-term Maintenance of CD4 T Cell Memory Responses to Malaria Antigens in Malian Children Coinfected with Schistosoma haematobium. Frontiers in Immunology, 2017, 8, 1995.	2.2	7
41	Spatio-Temporal Dynamics of Asymptomatic Malaria: Bridging the Gap Between Annual Malaria Resurgences in a Sahelian Environment. American Journal of Tropical Medicine and Hygiene, 2017, 97, 1761-1769.	0.6	28
42	Prevalence of Clinical and Subclinical Plasmodium falciparum and Plasmodium vivax Malaria in Two Remote Rural Communities on the Myanmarâ€“China Border. American Journal of Tropical Medicine and Hygiene, 2017, 97, 1524-1531.	0.6	24
43	Plasmodium vivax Infections over 3 Years in Duffy Blood Group Negative Malians in Bandiagara, Mali. American Journal of Tropical Medicine and Hygiene, 2017, 97, 744-752.	0.6	52
44	TSCQ study: a randomized, controlled, open-label trial of daily trimethoprim-sulfamethoxazole or weekly chloroquine among adults on antiretroviral therapy in Malawi: study protocol for a randomized controlled trial. Trials, 2016, 17, 322.	0.7	8
45	Presidential Address: Tropical Medicine in War and Peace â€. American Journal of Tropical Medicine and Hygiene, 2016, 95, 5-9.	0.6	8
46	Strain-specific Plasmodium falciparum multifunctional CD4+ T cell cytokine expression in Malian children immunized with the FMP2.1/AS02A vaccine candidate. Vaccine, 2016, 34, 2546-2555.	1.7	10
47	Protection against malaria at 1 year and immune correlates following PfSPZ vaccination. Nature Medicine, 2016, 22, 614-623.	15.2	313
48	Expression of complement and toll-like receptor pathway genes is associated with malaria severity in Mali: a pilot case control study. Malaria Journal, 2016, 15, 150.	0.8	18
49	The (International) American Society of Tropical Medicine and Hygiene. American Journal of Tropical Medicine and Hygiene, 2016, 95, 980-982.	0.6	1
50	Optimizing Intradermal Administration of Cryopreserved Plasmodium falciparum Sporozoites in Controlled Human Malaria Infection. American Journal of Tropical Medicine and Hygiene, 2015, 93, 1274-1284.	0.6	23
51	Artemisinin resistance in Myanmar. Lancet Infectious Diseases, The, 2015, 15, 1001-1002.	4.6	2
52	An ultrasensitive reverse transcription polymerase chain reaction assay to detect asymptomatic low-density Plasmodium falciparum and Plasmodium vivax infections in small volume blood samples. Malaria Journal, 2015, 14, 520.	0.8	51
53	Seroreactivity to a Large Panel of Field-Derived Plasmodium falciparum Apical Membrane Antigen 1 and Merozoite Surface Protein 1 Variants Reflects Seasonal and Lifetime Acquired Responses to Malaria. American Journal of Tropical Medicine and Hygiene, 2015, 92, 9-12.	0.6	20
54	Plasmodium falciparum field isolates from areas of repeated emergence of drug resistant malaria show no evidence of hypermutator phenotype. Infection, Genetics and Evolution, 2015, 30, 318-322.	1.0	18

#	Article	IF	Citations
55	Genetic architecture of artemisinin-resistant Plasmodium falciparum. Nature Genetics, 2015, 47, 226-234.	9.4	515
56	Polymorphisms in the K13-Propeller Gene in Artemisinin-Susceptible Plasmodium falciparum Parasites from Bougoula-Hameau and Bandiagara, Mali. American Journal of Tropical Medicine and Hygiene, 2015, 92, 1202-1206.	0.6	89
57	Persistence of Sulfadoxine-Pyrimethamine Resistance Despite Reduction of Drug Pressure in Malawi. Journal of Infectious Diseases, 2015, 212, 694-701.	1.9	25
58	A Single Mutation in K13 Predominates in Southern China and Is Associated With Delayed Clearance ofPlasmodium falciparumFollowing Artemisinin Treatment. Journal of Infectious Diseases, 2015, 212, 1629-1635.	1.9	125
59	Differential Recognition of Terminal Extracellular Plasmodium falciparum VAR2CSA Domains by Sera from Multigravid, Malaria-Exposed Malian Women. American Journal of Tropical Medicine and Hygiene, 2015, 92, 1190-1194.	0.6	11
60	Designing malaria vaccines to circumvent antigen variability. Vaccine, 2015, 33, 7506-7512.	1.7	54
61	Vaccine-Resistant Malaria. New England Journal of Medicine, 2015, 373, 2082-2083.	13.9	15
62	Hemoglobin C Trait Provides Protection From Clinical Falciparum Malaria in Malian Children. Journal of Infectious Diseases, 2015, 212, 1778-1786.	1.9	13
63	Independent Emergence of Artemisinin Resistance Mutations Among Plasmodium falciparum in Southeast Asia. Journal of Infectious Diseases, 2015, 211, 670-679.	1.9	368
64	Spread of Artemisinin Resistance in Plasmodium falciparum Malaria. New England Journal of Medicine, 2014, 371, 411-423.	13.9	1,753
65	Ordered Accumulation of Mutations Conferring Resistance to Sulfadoxine-Pyrimethamine in the Plasmodium falciparum Parasite. Journal of Infectious Diseases, 2014, 209, 130-139.	1.9	29
66	Chloroquine-Azithromycin Combination Antimalarial Treatment Decreases Risk of Respiratory- and Gastrointestinal-Tract Infections in Malawian Children. Journal of Infectious Diseases, 2014, 210, 585-592.	1.9	12
67	Polymorphisms in Plasmodium falciparum Chloroquine Resistance Transporter and Multidrug Resistance 1 Genes: Parasite Risk Factors That Affect Treatment Outcomes for P. falciparum Malaria After Artemether-Lumefantrine and Artesunate-Amodiaquine. American Journal of Tropical Medicine and Hygiene, 2014, 91, 833-843.	0.6	204
68	Stable malaria incidence despite scaling up control strategies in a malaria vaccine-testing site in Mali. Malaria Journal, 2014, 13, 374.	0.8	47
69	Resistance nailed. Nature, 2014, 505, 30-31.	13.7	15
70	A microarray platform and novel SNP calling algorithm to evaluate Plasmodium falciparum field samples of low DNA quantity. BMC Genomics, 2014, 15, 719.	1.2	18
71	Return of Widespread Chloroquine-Sensitive Plasmodium falciparum to Malawi. Journal of Infectious Diseases, 2014, 210, 1110-1114.	1.9	79
72	External Quality Assurance of Malaria Nucleic Acid Testing for Clinical Trials and Eradication Surveillance. PLoS ONE, 2014, 9, e97398.	1.1	28

#	Article	IF	Citations
73	Variation in the Circumsporozoite Protein of Plasmodium falciparum: Vaccine Development Implications. PLoS ONE, 2014, 9, e101783.	1.1	22
74	The Jeremiah Metzger lecture: new additions to the toolbox for global malaria eradication. Transactions of the American Clinical and Climatological Association, 2014, 125, 271-80.	0.9	1
75	Spatio-temporal analysis of malaria within a transmission season in Bandiagara, Mali. Malaria Journal, 2013, 12, 82.	0.8	44
76	Genetic loci associated with delayed clearance of Plasmodium falciparum following artemisinin treatment in Southeast Asia. Proceedings of the National Academy of Sciences of the United States of America, 2013, 110, 240-245.	3.3	242
77	Molecular Basis of Allele-Specific Efficacy of a Blood-Stage Malaria Vaccine: Vaccine Development Implications. Journal of Infectious Diseases, 2013, 207, 511-519.	1.9	66
78	A comprehensive survey of polymorphisms conferring anti-malarial resistance in Plasmodium falciparum across Pakistan. Malaria Journal, 2013, 12, 300.	0.8	23
79	Monitoring antifolate resistance in intermittent preventive therapy for malaria. Trends in Parasitology, 2013, 29, 497-504.	1.5	27
80	Multiple populations of artemisinin-resistant Plasmodium falciparum in Cambodia. Nature Genetics, 2013, 45, 648-655.	9.4	424
81	Seroreactivity to Plasmodium falciparum Erythrocyte Membrane Protein 1 Intracellular Domain in Malaria-Exposed Children and Adults. Journal of Infectious Diseases, 2013, 208, 1514-1519.	1.9	20
82	Successful Human Infection with P. falciparum Using Three Aseptic Anopheles stephensi Mosquitoes: A New Model for Controlled Human Malaria Infection. PLoS ONE, 2013, 8, e68969.	1.1	26
83	Extended Safety, Immunogenicity and Efficacy of a Blood-Stage Malaria Vaccine in Malian Children: 24-Month Follow-Up of a Randomized, Double-Blinded Phase 2 Trial. PLoS ONE, 2013, 8, e79323.	1.1	38
84	Malaria Vaccines. , 2013, , 171-197.		0
85	No Evidence of Delayed Parasite Clearance after Oral Artesunate Treatment of Uncomplicated Falciparum Malaria in Mali. American Journal of Tropical Medicine and Hygiene, 2012, 87, 23-28.	0.6	58
86	Next Generation Sequencing to Detect Variation in the Plasmodium falciparum Circumsporozoite Protein. American Journal of Tropical Medicine and Hygiene, 2012, 86, 775-781.	0.6	30
87	Artemisinin-Resistant Malaria: Research Challenges, Opportunities, and Public Health Implications. American Journal of Tropical Medicine and Hygiene, 2012, 87, 231-241.	0.6	136
88	Vaccines for Malaria: How Close Are We?. Annual Review of Medicine, 2012, 63, 345-357.	5.0	50
89	Reduced T Regulatory Cell Response during Acute Plasmodium falciparum Infection in Malian Children Co-Infected with Schistosoma haematobium. PLoS ONE, 2012, 7, e31647.	1.1	24
90	Antigen-Specific B Memory Cell Responses to Plasmodium falciparum Malaria Antigens and Schistosoma haematobium Antigens in Co-Infected Malian Children. PLoS ONE, 2012, 7, e37868.	1.1	15

#	Article	IF	Citations
91	A Longitudinal Trial Comparing Chloroquine as Monotherapy or in Combination with Artesunate, Azithromycin or Atovaquone-Proguanil to Treat Malaria. PLoS ONE, 2012, 7, e42284.	1.1	30
92	Analysis of Plasmodium falciparum diversity in natural infections by deep sequencing. Nature, 2012, 487, 375-379.	13.7	450
93	Using CF11 cellulose columns to inexpensively and effectively remove human DNA from Plasmodium falciparum-infected whole blood samples. Malaria Journal, 2012, 11, 41.	0.8	79
94	Malaria Genomics and the Developing World. Advances in Microbial Ecology, 2012, , 117-130.	0.1	0
95	The Threat of Artemisinin-Resistant Malaria. New England Journal of Medicine, 2011, 365, 1073-1075.	13.9	232
96	A Research Agenda to Underpin Malaria Eradication. PLoS Medicine, 2011, 8, e1000406.	3.9	565
97	A Field Trial to Assess a Blood-Stage Malaria Vaccine. New England Journal of Medicine, 2011, 365, 1004-1013.	13.9	311
98	Limited Geographical Origin and Global Spread of Sulfadoxine-Resistant dhps Alleles in Plasmodium falciparum Populations. Journal of Infectious Diseases, 2011, 204, 1980-1988.	1.9	74
99	Return of Chloroquineâ€Susceptible Falciparum Malaria in Malawi Was a Reexpansion of Diverse Susceptible Parasites. Journal of Infectious Diseases, 2010, 202, 801-808.	1.9	126
100	Low infectivity of Plasmodium falciparum gametocytes to Anopheles gambiae following treatment with sulfadoxineâ€“pyrimethamine in Mali. International Journal for Parasitology, 2010, 40, 1213-1220.	1.3	34
101	Plasmodium falciparum Malaria Challenge by the Bite of Aseptic Anopheles stephensi Mosquitoes: Results of a Randomized Infectivity Trial. PLoS ONE, 2010, 5, e13490.	1.1	42
102	Development of a metabolically active, non-replicating sporozoite vaccine to preventPlasmodium falciparummalaria. Hum Vaccin, 2010, 6, 97-106.	2.4	258
103	Lack of allele-specific efficacy of a bivalent AMA1 malaria vaccine. Malaria Journal, 2010, 9, 175.	0.8	61
104	Safety and Immunogenicity of an AMA1 Malaria Vaccine in Malian Children: Results of a Phase 1 Randomized Controlled Trial. PLoS ONE, 2010, 5, e9041.	1.1	54
105	Extreme Polymorphism in a Vaccine Antigen and Risk of Clinical Malaria: Implications for Vaccine Development. Science Translational Medicine, 2009, 1, 2ra5.	5.8	154
106	High Levels of Plasmodium falciparum Rosetting in All Clinical Forms of Severe Malaria in African Children. American Journal of Tropical Medicine and Hygiene, 2009, 81, 987-993.	0.6	94
107	The Potential Role of Vaccines in the Elimination of Falciparum Malaria and the Eventual Eradication of Malaria. Journal of Infectious Diseases, 2009, 200, 1646-1649.	1.9	57
108	Genome-wide and fine-resolution association analysis of malaria in West Africa. Nature Genetics, 2009, 41, 657-665.	9.4	345

#	Article	IF	Citations
109	The evolution of drug-resistant malaria. Transactions of the Royal Society of Tropical Medicine and Hygiene, 2009, 103, S11-S14.	0.7	109
110	Cell-mediated immunity elicited by the blood stage malaria vaccine apical membrane antigen 1 in Malian adults: Results of a Phase I randomized trial. Vaccine, 2009, 27, 2171-2176.	1.7	21
111	A network to monitor antimalarial drug resistance: a plan for moving forward. Trends in Parasitology, 2008, 24, 43-48.	1.5	46
112	Sulfadoxine-Pyrimethamineâ€"Based Combinations for Malaria: A Randomised Blinded Trial to Compare Efficacy, Safety and Selection of Resistance in Malawi. PLoS ONE, 2008, 3, e1578.	1.1	31
113	Safety and Immunogenicity of an AMA-1 Malaria Vaccine in Malian Adults: Results of a Phase 1 Randomized Controlled Trial. PLoS ONE, 2008, 3, e1465.	1.1	104
114	Dynamics of Polymorphism in a Malaria Vaccine Antigen at a Vaccine-Testing Site in Mali. PLoS Medicine, 2007, 4, e93.	3.9	94
115	Combination Therapy for Malaria: Mission Accomplished?. Clinical Infectious Diseases, 2007, 44, 1075-1077.	2.9	12
116	Blood group O protects against severe Plasmodium falciparum malaria through the mechanism of reduced rosetting. Proceedings of the National Academy of Sciences of the United States of America, 2007, 104, 17471-17476.	3.3	251
117	World Antimalarial Resistance Network (WARN) IV: Clinical pharmacology. Malaria Journal, 2007, 6, 122.	0.8	45
118	World Antimalarial Resistance Network (WARN) III: Molecular markers for drug resistant malaria. Malaria Journal, 2007, 6, 121.	0.8	99
119	World Antimalarial Resistance Network I: Clinical efficacy of antimalarial drugs. Malaria Journal, 2007, 6, 119.	0.8	57
120	The rationale and plan for creating a World Antimalarial Resistance Network (WARN). Malaria Journal, 2007, 6, 118.	0.8	37
121	PneumocystisPneumonia in HIV-positive Adults, Malawi1. Emerging Infectious Diseases, 2007, 13, 325-328.	2.0	29
122	The interaction between HIV and malaria in Africa. Current Infectious Disease Reports, 2007, 9, 47-54.	1.3	29
123	RARE PLASMODIUM FALCIPARUM MEROZOITE SURFACE PROTEIN 1 19-KDA (MSP-119) HAPLOTYPES IDENTIFIED IN MALI USING HIGH-THROUGHPUT GENOTYPING METHODS. American Journal of Tropical Medicine and Hygiene, 2007, 76, 855-859.	0.6	5
124	Monitoring and Deterring Drug-Resistant Malaria in the Era of Combination Therapy. American Journal of Tropical Medicine and Hygiene, 2007, 77, 160-169.	0.6	57
125	Selection of Antifolate-Resistant Plasmodium falciparum by Sulfadoxine-Pyrimethamine Treatment and Infectivity to Anopheles Mosquitoes. American Journal of Tropical Medicine and Hygiene, 2007, 77, 438-443.	0.6	23
126	Platelet-mediated clumping of Plasmodium falciparum infected erythrocytes is associated with high parasitemia but not severe clinical manifestations of malaria in African children. American Journal of Tropical Medicine and Hygiene, 2007, 77, 943-6.	0.6	14

#	Article	IF	Citations
127	Short report: rare Plasmodium falciparum merozoite surface protein 1 19-kda (msp-1(19)) haplotypes identified in Mali using high-throughput genotyping methods. American Journal of Tropical Medicine and Hygiene, 2007, 76, 855-9.	0.6	5
128	Selection of antifolate-resistant Plasmodium falciparum by sulfadoxine-pyrimethamine treatment and infectivity to Anopheles mosquitoes. American Journal of Tropical Medicine and Hygiene, 2007, 77, 438-43.	0.6	21
129	Monitoring and deterring drug-resistant malaria in the era of combination therapy. American Journal of Tropical Medicine and Hygiene, 2007, 77, 160-9.	0.6	42
130	A high-throughput method for quantifying alleles and haplotypes of the malaria vaccine candidate Plasmodium falciparum merozoite surface protein-1 19 kDa. Malaria Journal, 2006, 5, 31.	0.8	36
131	Return of Chloroquine Antimalarial Efficacy in Malawi. New England Journal of Medicine, 2006, 355, 1959-1966.	13.9	369
132	Observational Cohort Study of HIV-Infected African Children. Pediatric Infectious Disease Journal, 2006, 25, 623-627.	1.1	26
133	Differential var gene transcription in Plasmodium falciparum isolates from patients with cerebral malaria compared to hyperparasitaemia. Molecular and Biochemical Parasitology, 2006, 150, 211-218.	0.5	180
134	Impact of HIVâ€Associated Immunosuppression on Malaria Infection and Disease in Malawi. Journal of Infectious Diseases, 2006, 193, 872-878.	1.9	95
135	Effects of Concomitant Schistosoma haematobium Infection on the Serum Cytokine Levels Elicited by Acute Plasmodium falciparum Malaria Infection in Malian Children. Infection and Immunity, 2006, 74, 5718-5724.	1.0	62
136	Reply to Muula. Journal of Infectious Diseases, 2006, 194, 1188-1189.	1.9	0
137	Safety and Allele-Specific Immunogenicity of a Malaria Vaccine in Malian Adults: Results of a Phase I Randomized Trial. PLOS Clinical Trials, 2006, 1, e34.	3.5	64
138	LOW MULTIPLICATION RATES OF AFRICAN PLASMODIUM FALCIPARUM ISOLATES AND LACK OF ASSOCIATION OF MULTIPLICATION RATE AND RED BLOOD CELL SELECTIVITY WITH MALARIA VIRULENCE. American Journal of Tropical Medicine and Hygiene, 2006, 74, 554-563.	0.6	45
139	Low multiplication rates of African Plasmodium falciparum isolates and lack of association of multiplication rate and red blood cell selectivity with malaria virulence. American Journal of Tropical Medicine and Hygiene, 2006, 74, 554-63.	0.6	37
140	Serum antibody levels to glycosylphosphatidylinositols in specimens derived from matched Malian children with severe or uncomplicated Plasmodium falciparum malaria and healthy controls. American Journal of Tropical Medicine and Hygiene, 2006, 75, 199-204.	0.6	7
141	Cotrimoxazole prophylaxis and malaria in Africa: Have the important questions been answered?. American Journal of Tropical Medicine and Hygiene, 2006, 75, 373-4.	0.6	5
142	Mechanisms of Resistance of Malaria Parasites to Antifolates. Pharmacological Reviews, 2005, 57, 117-145.	7.1	400
143	Association between the Pharmacokinetics and In Vivo Therapeutic Efficacy of Sulfadoxine-Pyrimethamine in Malawian Children. Antimicrobial Agents and Chemotherapy, 2005, 49, 3601-3606.	1.4	33
144	Impact of Trimethoprimâ€Sulfamethoxazole Prophylaxis on Falciparum Malaria Infection and Disease. Journal of Infectious Diseases, 2005, 192, 1823-1829.	1.9	119

#	Article	IF	Citations
145	HLA-A2 Supertype-Restricted Cell-Mediated Immunity by Peripheral Blood Mononuclear Cells Derived from Malian Children with Severe or Uncomplicated Plasmodium falciparum Malaria and Healthy Controls. Infection and Immunity, 2005, 73, 5799-5808.	1.0	29
146	Community Permission for Medical Research in Developing Countries. Clinical Infectious Diseases, 2005, 41, 255-259.	2.9	148
147	Towards an RTS,S-based, multi-stage, multi-antigen vaccine against falciparum malaria: progress at the Walter Reed Army Institute of Research. Vaccine, 2005, 23, 2243-2250.	1.7	174
148	ASSOCIATION OF SCHISTOSOMA HAEMATOBIUM INFECTION WITH PROTECTION AGAINST ACUTE PLASMODIUM FALCIPARUM MALARIA IN MALIAN CHILDREN. American Journal of Tropical Medicine and Hygiene, 2005, 73, 1124-1130.	0.6	118
149	Association of Schistosoma haematobium infection with protection against acute Plasmodium falciparum malaria in Malian children. American Journal of Tropical Medicine and Hygiene, 2005, 73, 1124-30.	0.6	75
150	Blood folate concentrations and in vivo sulfadoxine-pyrimethamine failure in Malawian children with uncomplicated Plasmodium falciparum malaria. American Journal of Tropical Medicine and Hygiene, 2005, 72, 267-72.	0.6	16
151	A community-based study of the incidence of trimethoprim-sulfamethoxazole-preventable infections in Malawian adults living with HIV. Journal of Acquired Immune Deficiency Syndromes (1999), 2005, 39, 626-31.	0.9	39
152	Molecular Diagnosis of Resistance to Antimalarial Drugs during Epidemics and in War Zones. Journal of Infectious Diseases, 2004, 190, 853-855.	1.9	52
153	Withdrawing antimalarial drugs: impact on parasite resistance and implications for malaria treatment policies. Drug Resistance Updates, 2004, 7, 279-288.	6.5	58
154	Incidence of severe Plasmodium falciparum malaria as a primary endpoint for vaccine efficacy trials in Bandiagara, Mali. Vaccine, 2004, 22, 3169-3174.	1.7	45
155	A comparison of anemia in hemoglobin C and normal hemoglobin A children with Plasmodium falciparum malaria. Acta Tropica, 2004, 90, 295-299.	0.9	15
156	Sustained clinical efficacy of sulfadoxine-pyrimethamine for uncomplicated falciparum malaria in Malawi after 10 years as first line treatment: five year prospective study. BMJ: British Medical Journal, 2004, 328, 545.	2.4	81
157	Monitoring antimalarial drug resistance: making the most of the tools at hand. Journal of Experimental Biology, 2003, 206, 3745-3752.	0.8	95
158	Reemergence of Chloroquineâ€SensitivePlasmodium falciparumMalaria after Cessation of Chloroquine Use in Malawi. Journal of Infectious Diseases, 2003, 187, 1870-1875.	1.9	453
159	ASSOCIATION OF INTRALEUKOCYTIC PLASMODIUM FALCIPARUM MALARIA PIGMENT WITH DISEASE SEVERITY, CLINICAL MANIFESTATIONS, AND PROGNOSIS IN SEVERE MALARIA. American Journal of Tropical Medicine and Hygiene, 2003, 69, 253-259.	0.6	103
160	CLEARANCE OF DRUG-RESISTANT PARASITES AS A MODEL FOR PROTECTIVE IMMUNITY IN PLASMODIUM FALCIPARUM MALARIA. American Journal of Tropical Medicine and Hygiene, 2003, 69, 558-563.	0.6	159
161	Association of intraleukocytic Plasmodium falciparum malaria pigment with disease severity, clinical manifestations, and prognosis in severe malaria. American Journal of Tropical Medicine and Hygiene, 2003, 69, 253-9.	0.6	57
162	Clearance of drug-resistant parasites as a model for protective immunity in Plasmodium falciparum malaria. American Journal of Tropical Medicine and Hygiene, 2003, 69, 558-63.	0.6	89

#	Article	IF	Citations
163	Molecular Markers for Failure of Sulfadoxineâ€Pyrimethamine and Chlorproguanilâ€Dapsone Treatment ofPlasmodium falciparumMalaria. Journal of Infectious Diseases, 2002, 185, 380-388.	1.9	452
164	Determinants of Treatment Response to Sulfadoxine-Pyrimethamine and Subsequent Transmission Potential in Falciparum Malaria. American Journal of Epidemiology, 2002, 156, 230-238.	1.6	83
165	Origin and Dissemination ofPlasmodium falciparumDrugâ€Resistance Mutations in South America. Journal of Infectious Diseases, 2002, 186, 999-1006.	1.9	163
166	Genetics of drug-resistant Plasmodium falciparum malaria in the Venezuelan state of Bolivar.. American Journal of Tropical Medicine and Hygiene, 2002, 67, 400-405.	0.6	39
167	Impact of preseason treatment on incidence of falciparum malaria and parasite density at a site for testing malaria vaccines in Bandiagara, Mali.. American Journal of Tropical Medicine and Hygiene, 2002, 67, 604-610.	0.6	66
168	Conservation of a novel vacuolar transporter in Plasmodium species and its central role in chloroquine resistance of P. falciparum. Current Opinion in Microbiology, 2001, 4, 415-420.	2.3	44
169	Application of a molecular marker for surveillance of chloroquine-resistant falciparum malaria. Lancet, The, 2001, 358, 890-891.	6.3	164
170	Plasmodium falciparum crossresistance between trimethoprim and pyrimethamine. Lancet, The, 2001, 358, 1066-1067.	6.3	125
171	A bifunctional dihydrofolate synthetaseâ€“folylpolyglutamate synthetase in Plasmodium falciparum identified by functional complementation in yeast and bacteria. Molecular and Biochemical Parasitology, 2001, 112, 239-252.	0.5	41
172	Pyrimethamineâ€“sulfadoxine resistance in Plasmodium falciparum: what next?. Trends in Parasitology, 2001, 17, 582-588.	1.5	329
173	Pyrimethamineâ€“sulfadoxine resistance in Plasmodium falciparum: what next?. Trends in Parasitology, 2001, 17, 570-571.	1.5	14
174	A Molecular Marker for Chloroquine-Resistant Falciparum Malaria. New England Journal of Medicine, 2001, 344, 257-263.	13.9	873
175	Hemoglobin C associated with protection from severe malaria in the Dogon of Mali, a West African population with a low prevalence of hemoglobin S. Blood, 2000, 96, 2358-2363.	0.6	169
176	Antifolate resistance due to new and known Plasmodium falciparum dihydrofolate reductase mutations expressed in yeast. Molecular and Biochemical Parasitology, 1998, 94, 205-214.	0.5	87
177	Molecular assays for surveillance of antifolate-resistant malaria. Lancet, The, 1998, 351, 1629-1630.	6.3	93
178	P. falciparum dihydrofolate reductase and dihydropteroate synthase mutations: epidemiology and role in clinical resistance to antifolates. Drug Resistance Updates, 1998, 1, 389-396.	6.5	120
179	Community Pyrimethamine-Sulfadoxine Use and Prevalence of Resistant Plasmodium falciparum Genotypes in Mali: A Model for Deterring Resistance. American Journal of Tropical Medicine and Hygiene, 1996, 55, 467-471.	0.6	68
180	Pyrimethamine and Proguanil Resistance-Conferring Mutations in Plasmodium falciparum Dihydrofolate Reductase: Polymerase Chain Reaction Methods for Surveillance in Africa. American Journal of Tropical Medicine and Hygiene, 1995, 52, 565-568.	0.6	577

#	Article	IF	Citations
181	Malaria: Clinical and Epidemiological Aspects. , 0, , 633-641.		2